Navigation Links
A new study by John Hopkins University proposes formula for good health

ver again, this time with a different diet. The process was repeated until all participants ate all three.

Researchers monitored each participant's levels of blood pressure, cholesterol and triglycerides on each diet. These measurements were then factored into a standard mathematical model, called the Framingham risk equation, for estimating heart disease risk.

According to Appel, the OmniHeart study results reconfirm the powerful effects of a diet-based approach to improving someone's cardiovascular risk profile, for blood pressure and cholesterol levels, and lowering their overall risk of heart disease. The OmniHeart Collaborative Research Group, which conducted this study, plans further research on the effects of carbohydrate on heart disease and its risk factors.

Source: John Hopkins Medical institute
'"/>




Page: 1 2 3

Related medicine news :

1. A new study surpasses Gene Therapy Hurdle
2. A question on study of Adult Stem Cell
3. Marijuana gateway theory strengthened by study of twins
4. Old theory of adaptation confirmed by new study
5. Gene study links endometriosis, infertility
6. Mutant sperm beat out healthy brethren in study
7. New study questions consumption of milk for bone growth
8. New study questions consumption of milk for bone growth
9. Going to GP may delay cancer diagnosis, says new study
10. Drug addiction can be genetical, says study
11. Autism epidemic is a myth- says a new study
Post Your Comments:
(Date:11/21/2008)...all/ -- Heska Corporation,(Nasdaq: HSKA ) today... of,Security Analysts, 12th Annual Biotech and Sp...1177 Avenue of the Americas, 2nd Floor in New York...:35 a.m. Eastern Time (7:35 a.m.,Mountain Time) a...weeks,following the presentation through a link u...
(Date:11/21/2008)...ique to combat cancer, study says, , ,...archers have discovered that some cancer cells use...ight lead to new treatments that starve and kill t...ells in the body need to produce energy. They do t...uires oxygen. Compared with normal cells, tumor ce...
(Date:11/21/2008)...ire/ -- U.S. News & World Report and the Natio...BlueChoice(R) HealthPlan of South Carolina in the ...ished in U.S. News & World Report,s issue this...ks the nation,s best health plans based on clinica...ion scores. NCQA and U.S. News & World Report ...
(Date:11/21/2008)...production of neural stem cells , , FRID...mice, exercise appears to reverse the decline in t...h aging, Taiwanese researchers report. , This r...ave off aging appears to be due to exercise,s abil...or the production of new brain cells. , "As we...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Exercise Keeps the Brain Young 2
...d out the increasing problem of super bugs to the ... farmlands. Super bugs are a new kind of microorga... affected by a wide range of antibiotics. The rese...ional Center and others who together had published...
...e treatment of osteoporosis is useful, but changes...tion. Nowadays the main treatment options are anti...r patients with previous fractures, treatment with...formation is preferable, and this is now possible ...
...July edition of the Journal of Neurosurgery sugges...everity of cases of constriction of blood vessels ...id haemorrhage (SAH). Normally constriction of b...following a SAH and this leads to strokes and neur...
...n chronic obstructive pulmonary disease (COPD) sai...en useful for patients of this disease to have imp...ructive pulmonary disease (COPD) are lung diseases...itions like lung tissue destruction, airway inflam...
Other Medicine News:Health News:The Benefits of Strontium in the treatment for Osteoporosis Questioned 2Health News:Clazosentan May help to Improve Blood Circulation after Brain Hemorrhage due to burst Aneurysm 2
(Date:11/19/2008)...ritical enzyme,s regulation may hold key to unders..., , MEMPHIS, Tenn., Nov. 19 /PRNewswire-USN...earch Hospital have gained new insights into regul...d calpains. , , As the cell,s molecular ov...ocesses, including the movement of cells in tissue...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
(Date:11/13/2008)...all/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leading ...agnostics, medical imaging systems and surgical pr...f women, today announced the results of the,Cervis...sta HPV high-risk,test is currently under review b...ed in the European Union (EU) early in 2009. The c...
(Date:11/12/2008)...12 Surgeons,at the University of R...-specific CTA data can be converted to an endovasc...th high face validity. The surgeons,"strongly agre...w,increased patient safety and efficiency of inst...scopy time and the amount of contrast used, and,th...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 1Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 2BioCryst Provides Forodesine HCl Update 994 1BioCryst Provides Forodesine HCl Update 994 2BioCryst Provides Forodesine HCl Update 994 3BioCryst Provides Forodesine HCl Update 994 4BioCryst Provides Forodesine HCl Update 994 5Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 1Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 4This is your brain on violent media 7728 1This is your brain on violent media 7728 2
...ta Presented at the American Academy of Neurology ...tion in Partial Seizures, BOSTON, May 01, 2007 /PR...ed today at the American Academy of Neurology (AAN...ly extended release,formulation of Lamictal(R) (la...ients with partial epilepsy with and without,secon...
...Study of over 7,700 women published today shows re...rcent in hip fractures, EAST HANOVER, N.J., May 02...Reclast(R) (zoledronic acid) Injection significant...tic bone fractures,over three years in women with ... today in The New England Journal of Medicine,mar...
Other Medicine Technology:New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 2New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 3New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 4New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX4-S system consolidates DATs, TDMs and other esoteric tests in one workstation, targeted to the mid-size lab that processes 50-200 samples per day. Like all SYNCHRON CX super systems,
It takes powerful technology to increase laboratory efficiency and worker safety, and still lower costs. It takes the new SYNCHRON LX20 PRO, offering features that you will not find on any other chem
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance.
Medicine Products: